Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

1. Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial

Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear.To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients (...) with schizophrenia and predominant negative symptoms.The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included.Ten sessions of tDCS performed twice

2019 EvidenceUpdates

2. Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness

Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia (...) or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: January 3, 2019 Project Number: RC1053-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients with schizophrenia or bipolar disorder? What is the cost-effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. (PubMed)

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Schizophrenia is one of the most common, burdensome, and costly psychiatric disorders in adults worldwide. Antipsychotic drugs are its treatment of choice, but there is controversy about which agent should be used. We aimed to compare and rank antipsychotics by quantifying information from randomised controlled (...) of schizophrenia or related disorders. We excluded studies in patients with treatment resistance, first episode, predominant negative or depressive symptoms, concomitant medical illnesses, and relapse-prevention studies. Our primary outcome was change in overall symptoms measured with standardised rating scales. We also extracted data for eight efficacy and eight safety outcomes. Differences in the findings of the studies were explored in metaregressions and sensitivity analyses. Effect size measures were

2019 Lancet

4. Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT

Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Minocycline had no effect on negative symptoms of schizophrenia and had no effect on any of the biomarkers of inflammation or neurodegeneration. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Bill Deakin 1, 2, 3, * , John Suckling 4, 5 , Paola Dazzan 6 , Eileen Joyce 7 , Stephen M Lawrie 8 , Rachel Upthegrove 9 , Nusrat Husain 10, 11 , Imran B Chaudhry 11, 12 , Graham Dunn 13, † , Peter B Jones 4

2019 NIHR HTA programme

5. Acetylsalicylic acid (aspirin) for schizophrenia. (PubMed)

Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS

2019 Cochrane

6. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. (PubMed)

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental illnesses. People with catatonia are more likely to require hospitalisation and highly supervised care than those without the disorder. They also have an increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug (...) therapies and electroconvulsive therapy.To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for catatonia in people with schizophrenia or other similar serious mental illnesses (SMIs).We updated our previous search (28 February 2007) by searching the Cochrane Schizophrenia Group's Study-Based Register of Trials (9 November 2016; 6 February 2019). This register is compiled by systematic searches of major resources (including CENTRAL, MEDLINE, Embase, AMED

2019 Cochrane

7. Cariprazine (Reagila) for the treatment of schizophrenia in adult patients.

Cariprazine (Reagila) for the treatment of schizophrenia in adult patients. 1 Published 13 May 2019 1 SMC2137 cariprazine 1.5mg, 3mg, 4.5mg and 6mg hard capsules (Reagila®) Recordati Pharmaceuticals Ltd 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission cariprazine (Reagila® (...) ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of schizophrenia in adult patients. SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature. In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic. Chairman Scottish Medicines Consortium www.scottishmedicines.or g.uk 2

2019 Scottish Medicines Consortium

8. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial

Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Schizophrenia is a leading cause of disability, and a shift from facility- to community-based care has been proposed to meet the resource challenges of mental healthcare in low- and middle-income countries. We hypothesized that the addition of mobile texting would improve (...) schizophrenia care in a resource-poor community setting compared with a community-based free-medicine program alone.In this 2-arm randomized controlled trial, 278 community-dwelling villagers (patient participants) were randomly selected from people with schizophrenia from 9 townships of Hunan, China, and were randomized 1:1 into 2 groups. The program participants were recruited between May 1, 2015, and August 31, 2015, and the intervention and follow-up took place between December 15, 2015, and July 1

2019 EvidenceUpdates

9. Haloperidol discontinuation for people with schizophrenia. (PubMed)

Haloperidol discontinuation for people with schizophrenia. Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews.To review the effects of haloperidol discontinuation (...) in people with schizophrenia who are stable on haloperidol.On 20 February 2015, 24 May 2017, and 12 January 2019, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including trial registers.We included clinical trials randomising adults with schizophrenia or related disorders who were receiving haloperidol, and were stable. We included trials that randomised such participants to either continue their current treatment with haloperidol or discontinue their haloperidol

2019 Cochrane

10. Yoga as part of a package of care versus non-standard care for schizophrenia. (PubMed)

Yoga as part of a package of care versus non-standard care for schizophrenia. Yoga is an ancient body-mind practice which originated in India and is popular in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine the efficacy of yoga delivered as a package of care versus non-standard care.To examine the effects of yoga as part of a package of care versus non-standard care for schizophrenia.We searched the Cochrane (...) Schizophrenia Group Trials Register (latest 15 May 2018) which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSS, AMED, PsychINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga as part of a package of care with non-standard care.There were

2019 Cochrane

11. Peer support for people with schizophrenia or other serious mental illness. (PubMed)

Peer support for people with schizophrenia or other serious mental illness. Peer support provides the opportunity for peers with experiential knowledge of a mental illness to give emotional, appraisal and informational assistance to current service users, and is becoming an important recovery-oriented approach in healthcare for people with mental illness.To assess the effects of peer-support interventions for people with schizophrenia or other serious mental disorders, compared to standard care (...) or other supportive or psychosocial interventions not from peers.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials on 27 July 2016 and 4 July 2017. There were no limitations regarding language, date, document type or publication status.We selected all randomised controlled clinical studies involving people diagnosed with schizophrenia or other related serious mental illness that compared peer support to standard care or other psychosocial interventions and that did

2019 Cochrane

12. Cognitive behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT

Cognitive behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT Cognitive behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1 (...) )"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Nine months of CBT for clozapine-resistant schizophrenia did not improve the primary outcome of total symptoms at 21 months, although symptoms seemed to be improved at end of treatment. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Anthony P Morrison 1, 2, *, † , Melissa Pyle 1, 2, † , Andrew Gumley 3 , Matthias Schwannauer 4 , Douglas Turkington 5 , Graeme MacLennan 6 , John Norrie 7 , Jemma Hudson 6 , Samantha Bowe 1 , Paul

2019 NIHR HTA programme

13. Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment

Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment CBT and treatment resistant schizophrenia Discover Portal Discover Portal Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment Published on 20 November 2018 doi: Cognitive behavioural therapy (CBT) does not improve residual symptoms for people taking clozapine for schizophrenia. Clozapine is the gold (...) -standard antipsychotic that is used when others have not worked. This NIHR-funded UK trial included 487 adults who had been taking clozapine for on average five years but were still symptomatic. Participants received either weekly CBT for nine months alongside usual treatment for schizophrenia or usual treatment alone. Usual treatment included clozapine or other medication and care from secondary, community or inpatient mental health services. There were no differences in favour of CBT at the main time

2019 NIHR Dissemination Centre

14. Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Discover Portal Discover Portal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 doi: For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug clozapine, adding amisulpride (another (...) particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007, approximately 30% of the total

2019 NIHR Dissemination Centre

15. Breast cancer screening rates for women with schizophrenia: a systematic review and meta-analysis

Breast cancer screening rates for women with schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

16. Adjunctive metformin for antipsychotic-induced dyslipidemia in patients with schizophrenia: a meta-analysis of randomized placebo-controlled trials

Adjunctive metformin for antipsychotic-induced dyslipidemia in patients with schizophrenia: a meta-analysis of randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

17. The prevalence of aggression in patients with schizophrenia estimated by using modified overt aggression scale: a systematic review and meta-analysis

The prevalence of aggression in patients with schizophrenia estimated by using modified overt aggression scale: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

18. Anti-depressive effect of antipsychotics in the treatment of schizophrenia: systematic review and meta-analysis of randomized placebo-controlled trials

Anti-depressive effect of antipsychotics in the treatment of schizophrenia: systematic review and meta-analysis of randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

19. A review of mental health diagnoses during the prodrome of schizophrenia

A review of mental health diagnoses during the prodrome of schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

20. The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis

The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO